Close menu




August 5th, 2025 | 07:30 CEST

Bayer, PanGenomic Health, Novo Nordisk: 3 stocks that could benefit from the USD 330 billion tech tsunami!

  • Health
  • healthtech
  • Biotechnology
  • Pharma
  • AI
Photo credits: pixabay.com

In 2025, the healthcare industry is being hit by a tech tsunami. Telemedicine and digital applications are revolutionizing diagnostics and treatment. Driven by AI, regulatory tailwinds, and rising patient demand, the market is exploding. Forecasts predict growth of up to USD 330 billion by 2029. Investors sense billion-dollar opportunities, especially where biotech meets big data and personalized solutions emerge. To benefit from these developments, key players like Bayer, PanGenomic Health, and Novo Nordisk are already positioning themselves today. We take a closer look at all three.

time to read: 5 minutes | Author: Armin Schulz
ISIN: BAYER AG NA O.N. | DE000BAY0017 , PANGENOMIC HEALTH INC | CA69842E4031 , NOVO NORDISK A/S | DK0062498333

Table of contents:


    Bayer – Digital impetus and course corrections

    Bayer is advancing its digital healthcare strategy far beyond basic teleconsultations. The focus is on practical digital tools such as INSIGHT PROSTATE, an augmented reality app that visualizes prostate cancer treatments and improves doctor-patient communication. Tools such as infuset support hemophilia patients in managing their daily therapy routines. At the same time, the Company is building platforms for medical professionals, such as Universo Médico, which offers continuing medical education content. The G4A accelerator program also promotes healthtech startups worldwide. The goal is clearly defined: better education, improved treatment adherence, and more efficient healthcare delivery chains.

    On July 31, Bayer significantly revised its full-year forecast upward. This is due to the strong performance of the pharmaceuticals business. Instead of an expected decline in revenue of up to 4%, the Company now anticipates currency-adjusted growth of up to 3%. Adjusted EBITDA is expected to reach EUR 9.7–10.2 billion, up from the previous target of EUR 9.5–10.0 billion. This turnaround is remarkable because it comes despite ongoing legal risks and reflects robust demand for established products and successful market launches. The division is clearly benefiting from its portfolio strength.

    Bayer is focusing on innovation in its agricultural business. With Icafolin, the Company submitted registration applications for a groundbreaking herbicide in the EU, the US, Brazil, and Canada. It is the first new mode of action in 30 years. It combats weed resistance and is scheduled to launch in Brazil in 2028. At the same time, the Company continues to be burdened by legal disputes. Provisions for US lawsuits, primarily for glyphosate, were increased by EUR 1.7 billion. Nevertheless, Bayer remains operationally robust, with the improved pharmaceuticals business currently more than offsetting these burdens. The share is currently available for purchase at EUR 27.83.

    PanGenomic Health – Digital bridge between naturopathy and AI

    PanGenomic Health from Canada relies on digital tools to make healthcare easier and more personalized. Its focus is on nature-based and holistic approaches, complemented by modern technology. At the core of its offering are apps such as NARA, which uses genetic and behavioral data to deliver tailored naturopathic recommendations. Mindleap provides stress management support and connects users with online therapists, while MUJN Diagnostics specializes in cognitive health diagnostics. These platforms are designed to complement traditional medical care in a low-threshold manner and put the user at the center.

    At the end of July, PanGenomic Health announced its next big step. Its new platform, NaraCare.AI, is set to launch in 2025. It combines the proven features of the NARA, Mindleap, and MUJN apps into a single ecosystem. The idea behind this is that the body and mind belong together. This platform seamlessly connects both aspects. Users receive AI-supported, customized tips for alternative treatments, including detailed information on how they work, dosages, and possible effects. The integrated online shop for suitable health products, which is set to launch even earlier, in fall 2025, will offer real added value.

    PanGenomic is thus addressing several rapidly growing markets. Telehealth, mobile health apps, and alternative medicine are booming, with double-digit growth rates. Demand for self-directed, preventive, and nature-based healthcare is particularly high in North America. Partnerships, such as with Psy Integrated Health, with which the Company plans to establish a joint diagnostic center, strengthen the foundation. The Company cleverly combines digital accessibility with personalized solutions and a direct sales channel. Although still young, it is positioning itself at the exciting intersection of technology, evidence-based naturopathy, and user empowerment. This is a field with significant expansion potential beyond its current core markets of Canada and the US. The stock is currently trading at CAD 1.52.

    Novo Nordisk – Digital patient apps and current challenges

    Novo Nordisk is driving forward the development of smart companions for patients that are particularly practical for everyday use. The Dibi (Temedica) app supports type 2 diabetics starting insulin therapy with tailored tips and anonymized data usage for research purposes. mySugr automatically synchronizes with the NovoPen 6 and Echo Plus smart pens to document insulin doses digitally. For obesity patients, the digital hub "Adipositas Care" offers reliable information, video consultations, and therapy support. The portfolio is complemented by AI coaching programs such as Noom, which promotes behavioral change. The result is a toolbox that strengthens therapy adherence and self-management.

    While the digital strategy is gaining momentum, the pharmaceutical giant is under pressure in the short term. A surprise profit warning recently caused the share price to plummet by 20%. Growth expectations for blockbusters such as Wegovy® and Ozempic® have been revised significantly downward. The reasons include delayed market penetration in Europe, price pressure from low-cost generic products in the US, and tougher competition from Eli Lilly's Zepbound™. At the same time, there was a surprise change in leadership. Lars Fruergaard Jørgensen is handing over to Mike Doustdar, the former head of international operations. He must now prove that he can find the operational levers to counter the market challenges.

    Despite the setback, Novo continues to focus on its pipeline. The pill version of Wegovy®, which could be approved in 2025, is promising. It would be a game changer for patients with a fear of needles. Studies are also underway on Amycretin, which showed weight loss of over 20% in initial data. However, political risks remain. The new US-EU trade agreement provides for 15% tariffs on pharmaceutical imports, a significant blow to Novo's US sales share of over 50%. Whether CEO Doustdar can counteract this will be crucial for the recovery of margins. The digital expansion will continue, but the current problems require navigational skills. The sell-off of the stock appears to be over for now. It is currently available for EUR 42.655.


    The digital healthcare market, with its potential of EUR 330 billion by 2029, offers massive opportunities, but the players are taking different paths. Bayer is currently impressing with a significant upward revision of its forecast for its pharmaceuticals business and is pushing ahead with practical digital solutions such as INSIGHT PROSTATE. PanGenomic Health is cleverly addressing the growing market for personalized naturopathy and is bundling its AI-supported tools in the new NaraCare.AI platform. Novo Nordisk is struggling with short-term setbacks such as a profit warning and management changes, but remains strongly committed to digital patient companions with a promising pipeline. Despite different challenges, all three are positioning themselves for the tech tsunami.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Jens Castner on November 20th, 2026 | 05:55 CET

    Invest now, cash in later: Deutsche Telekom, RE Royalties and Fresenius on a growth trajectory

    • Growth
    • Health
    • Telecommunications
    • Renewable energies
    • Fresenius
    • RE Royalties
    • Deutsche Telekom
    • Fibre optics
    • Mobile communications
    • Wind power
    • Solar

    In turbulent stock markets, investors seek stability. Dividend stocks are often seen as a rock in a storm: the payout provides a sense of security, regardless of what the share price is doing. But even a rock can develop cracks. Even a long-standing dividend aristocrat like Fresenius had to suspend its dividend once in recent years – and emerged stronger as a result. Sometimes, voluntarily forgoing a payout is the better choice. Deutsche Telekom cut its dividend to invest in growth, thereby jolting its share price out of its lethargy. RE Royalties is now taking a similar approach.

    Read

    Commented by Stefan Feulner on November 20th, 2026 | 05:55 CET

    Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

    • Biotechnology

    Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

    Read

    Commented by Carsten Mainitz on November 19th, 2026 | 05:20 CET

    Uranium and Reactor Technology: Standard Uranium, Cameco and SGL Carbon – Who Benefits Most from the Nuclear Comeback?

    • Uranium
    • Nuclear power
    • Nuclear energy
    • Reactors
    • Reactor technology
    • AI
    • Supply chains

    Nuclear power needs fresh supplies! Longer operating lifetimes, new reactors and power-hungry data centres are strengthening demand and fuelling optimism for the industry. Geopolitical tensions are pushing operators to secure supplies, while additional supply requires substantial capital and time. For investors, this opens up opportunities along the entire nuclear value chain. Standard Uranium starts at the very beginning, exploring for new deposits in Canada's Athabasca region. Cameco already generates revenue from uranium and fuel services and is also involved in reactor technology through Westinghouse. SGL Carbon, in turn, supplies speciality graphite for X-energy's reactors and recently secured another order worth around USD 90 million. Which company will take off now?

    Read